Medtronic has broadened its collaboration with Retia Medical by extending distribution of the Argos cardiac output monitor to hospitals across Western Europe. The expanded arrangement builds on the exclusive U.S. distribution agreement established in April 2025 and further strengthens the company’s perioperative and critical care portfolio with advanced hemodynamic monitoring capabilities. The Medtronic Distribution Deal is intended to increase access to technology designed to provide clinicians with detailed hemodynamic information for managing high-risk surgical patients and those receiving critical care.
The Argos system operates through a patient’s existing arterial line and uses a single reusable cable to connect with a radial blood pressure transducer. According to the companies, the monitor requires no calibration and features a multi-touch screen interface that can be operational within minutes. Training can be completed in less than five minutes, while the system eliminates the need for expensive disposable accessories. The expansion follows Medtronic’s continued efforts to enhance its Acute Care & Monitoring portfolio through additional patient-monitoring technologies.
A key feature of the Argos platform is its Multi-Beat Analysis (MBA) algorithm, developed by researchers at the Massachusetts Institute of Technology (MIT) and Michigan State University. Rather than evaluating one heartbeat at a time, MBA analyzes multiple heartbeats from the blood pressure signal, enabling direct modelling of a patient’s vascular resistance. Medtronic states that the system delivers accurate hemodynamic information across 10 parameters and maintains performance during variations in vasomotor tone, low cardiac output conditions and arrhythmias.
Commenting on the expansion, Marc DeMartini, Western Europe commercial VP of the ACM business at Medtronic, said: “Our focus is on helping clinicians navigate complexity with greater clarity. The Argos cardiac output monitor adds meaningful haemodynamic insight to our Acute Care & Monitoring portfolio and complements established technologies such as INVOS cerebral oximetry, supporting a more comprehensive view of patient status across perioperative and critical care environments. By bringing this technology to Western Europe, we are reinforcing our commitment to partner with healthcare systems as they work to deliver high-quality care in an increasingly resource-constrained environment.”
Marc Zemel, CEO of Retia Medical, added: “Medtronic is an ideal partner for Retia Medical as we expand access to the Argos cardiac output monitor in Western Europe. With a robust portfolio, deep customer relationships, and leadership in advancing acute care and monitoring technologies, Medtronic is uniquely positioned to help bring the benefits of our innovative solution to clinicians and patients across Western Europe. We look forward to working together to help to set a new standard in hemodynamic monitoring.” The Medtronic Distribution Deal marks the latest step in expanding the availability of the Argos platform in the region.
